Early Drug Development Group (E2DG) is a French interdisciplinary research group of medical oncologist and molecular biology experts. Their range of services are dedicated to biotech and MedTech start-ups or pharmaceutical companies to foster R&D programs in a time and cost-effective manner.
With more than 20 years of experience, E2DG can boost oncology programs thanks to its expertise in preclinical development and phase I clinical study.
Over the past 5 years they developed 18 drugs in oncology, 5 First-in-class drugs, 2 In phase I and sold one to the Big Pharma.
The main services offered by E2DG are:
- Management of R&D programs,
- Assistance on preclinical, regulatory strategies and phase I clinical trials
- Provision of their own facilities for preclinical, PK and Radiopharma
- Advice on reported preclinical and clinical data
EARLY DRUG DEVELOPMENT GROUP
1 Place Paul Verlaine
Christophe Mazars – CEO [email protected]